Nowa wersja platformy jest już dostępna.
Przejdź na


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2014 | 10 | 1 |
Tytuł artykułu

Trefoil factor 3 as a marker of intestinal cell damage during sepsis

Treść / Zawartość
Warianty tytułu
Języki publikacji
Objective: Gastrointestinal dysfunction or gut failure frequently occurs in seriously ill patients and can be responsible for multi-organ failure. Trefoil factor 3 (TFF3) was characterized for its role in reconstitution of an epithelial barrier after mucosal injury in the jejunum. The aims of our study was an analysis of TFF3 levels dynamics in patients with sepsis and the correlation of TFF3 with severity of sepsis and mortality. Methods: Prospective observational study, a ten days evaluation period in children aged 0-19 years with systemic inflammatory response syndrome or septic state. Blood tests to determine levels of TFF3 were obtained as long as the patient met the criteria for systemic inflammatory response syndrome or sepsis. Results: Analysis of dynamics revealed steady levels of TFF3 during the 10 day period evaluated. TFF3 levels could not differentiate between various septic conditions in patients until a marked organ dysfunction developed. Higher Area Under Curve was noticed between control group and patients with sepsis. We could not make any strong conclusions based on mortality model. Conclusions: Levels of TFF3 are elevated in paediatric patients with sepsis through organ dysfunction.
Słowa kluczowe

Opis fizyczny
  • University Children‘s Hospital,
    Department of Anesthesia and Intensive Care, Černopolní 9, Brno,
    62500, Czech Republic
  • Faculty of Medicine, Masaryk University, Černopolní 9,
    Brno, 62500, Czech Republic
  • University Children‘s Hospital,
    Department of Anesthesia and Intensive Care, Černopolní 9, Brno,
    62500, Czech Republic
  • University Children‘s Hospital,
    Department of Anesthesia and Intensive Care, Černopolní 9, Brno,
    62500, Czech Republic
  • [1] Derikx J.P., Poeze M., van Bijnen A.A., Buurman W.A., HeinemanE., Evidence for intestinal and liver epithelial cell injury in theearly phase of sepsis, Shock, 2007, 28, 544-548[WoS]
  • [2] Azzopardi N., Fenech M., Piscopo T., Sepsis, the Liver and theGut, Sepsis–An Ongoing and Significant Challenge, InTech,2012
  • [3] Puleo F., Arvanitakis M., Van Gossum A., Preiser J.C., Gut failurein the ICU, Semin Respir Crit Care Med., 2011, 32, 626-638[WoS]
  • [4] Mammen J.M.V.M., Matthews J.B.M., Mucosal repair in thegastrointestinal tract, Critical Care Medicine Healing Responsesin Critical Illness, 2003,31,S532-S537
  • [5] Thim L., A new family of growth factor-like peptides: ‘trefoil’disulphide loop structures as a common feature in breastcancer associated peptide (pS2), pancreatic spasmolyticpolypeptide (PSP) and frog skin peptides (spasmolysins), FEBSLett., 1989, 250, 85-90
  • [6] Hauser F., Poulsom R., Chinery R., Rogers L.A., HanbyA.M., Wright N.A., et al., hP1.B, a human P-domain peptidehomologous with rat intestinal trefoil factor, is expressed alsoin the ulcer-associated cell lineage and the uterus, Proc. Natl.Acad. Sci. USA, 1993, 90, 6961-6965
  • [7] Xian C.J., Howarth G.S., Mardell C.E., Cool J.C., Familari M.,Read L.C., et al., Temporal changes in TFF3 expression andjejunal morphology during methotrexate-induced damage andrepair, Am J Physiol, 1999,277, G785-G795
  • [8] Babyatsky M.W., deBeaumont M., Thim L., Podolsky D.K., Oraltrefoil peptides protect against ethanol- and indomethacininducedgastric injury in rats, Gastroenterology, 1996,110,489-497
  • [9] Schwarzberg H., Kalbacher H., Hoffmann W., Differentialbehavioral effects of TFF peptides: Injections of syntheticTFF3 into the ratamygdala, Pharmacol BiochemBehav,1999,62,173-178
  • [10] Goldstein B., Giroir B., Randolph A., International pediatricsepsis consensus conference: Definitions for sepsis and organdysfunction in pediatrics, Pediatr Crit Care Med, 2005, 6, 2-8[Crossref]
  • [11] Leteurtre S., Martinot A., Duhamel A., Gauvin F., GrandbastienB., Nam T.V., et al.. Development of a pediatric multiple organdysfunction score: use of two strategies, Med Decis Making,1999, 19, 399-410
  • [12] Ng E.W., Poon T.C., Lam H.S., Cheung H.M., Ma T.P., Chan K.Y.,et al., Gut-Associated Biomarkers L-FABP, I-FABP, and TFF3 andLIT Score for Diagnosis of Surgical Necrotizing Enterocolitis inPreterm Infants, Ann Surg. , 2013, 258, 1111-1118
  • [13] Vestergaard E.M., Poulsen S.S., Grønbaek H., LarsenR., Nielsen A.M., Ejskjaer K., et al., Development andevaluation of an ELISA for human trefoil factor 3, Clin Chem.,2002,48,1689-1695
  • [14] Moran P., Beasley H., Gorrell A., Martin E., Gribling P., Fuchs H.,et al., Human recombinant soluble decay accelerating factorinhibits complement activation in vitro and in vivo, J. Immunol.,1992, 149, 1736-1743
  • [15] Heeger P.S., Lalli P.N., Lin F., Valujskikh A., Liu J., Muqim N.,et al., Decay-accelerating factor modulates induction of T cellimmunity, J. Exp. Med., 2005, 201, 1523-1530
  • [16] Fink M.P., Delude R.L., Epithelial barrier dysfunction: aunifying theme to explain the pathogenesis of multiple organdysfunction at the cellular level, Crit Care Clin 2005, 2, 177-196
  • [17] Gatt M., Reddy B.S., MacFie J., Review article: bacterialtranslocation in the critically ill–evidence and methods ofprevention, Aliment Pharmacol Ther., 2007, 25, 741-757[WoS]
  • [18] Stephens R.C., Fidler K., Wilson P., Barclay G.R., Mythen M.G.,Dixon G.L., et al., Endotoxin immunity and the development ofthe systemic inflammatory response syndrome in critically illchildren, Intensive Care Med, 2006, 32, 286-294
Typ dokumentu
Identyfikator YADDA
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.